Responses
Regular Abstracts – Part 2
Combination Immunotherapies
897-B A DNAJB1-PRKACA fusion peptide vaccine combined with ipilimumab and nivolumab elicits polyclonal fusion-specific T cell responses in fibrolamellar carcinoma
Compose a Response to This Article
Other responses
No responses have been published for this article.
